<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092945</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2990</org_study_id>
    <nct_id>NCT05092945</nct_id>
  </id_info>
  <brief_title>Brown Adipose Tissue Metabolism in Type 2 Diabetes</brief_title>
  <acronym>GB8</acronym>
  <official_title>Quantifying Brown Adipose Tissue Thermogenesis in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activation of brown adipose tissue (BAT) by cold exposure.&#xD;
&#xD;
      BAT thermogenesis and BAT volume of metabolic activity will be assessed by&#xD;
      Positron-Emitting-Tomography (PET/CT) and MRI/MRS imaging and new pharmacological methods to&#xD;
      modulate BAT thermogenesis.&#xD;
&#xD;
      All previous data on the functioning of Brown Adipose Tissue (BAT) were obtained by&#xD;
      Positron-Emitting-Tomography (PET) imaging studies using fluorodeoxyglucose F18 ( [18F]-&#xD;
      FDG). This approach underestimates the actual activity of the BAT. In this study, the&#xD;
      investigator is going to use a new PET tracer (C11-palmitate) which is a fat molecule. This&#xD;
      will allow to quantify more accurately the activity of brown fat.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol includes three visits: the screening visit (V1) and two PET/MRI imaging&#xD;
      studies (V2 and V3) performed in random order at an interval of 7 to 14 days.&#xD;
&#xD;
      PET/ MRI studies will be performed with and without nicotinic acid. A total of 500 mg of&#xD;
      nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg,&#xD;
      through V2 (protocol A): one dose at time 0, 60 minutes, 120 minutes and 180 minutes.&#xD;
&#xD;
      During V2 and V3, participants will undergo Acute Cold Exposure to stimulate brown adipose&#xD;
      tissue.&#xD;
&#xD;
      The morning of each PET imaging study, the participants will follow an MRI acquisition to&#xD;
      determine hepatic, pancreatic, visceral and BAT lipid content, followed by an MRS acquisition&#xD;
      in the hepatic and cervico-thoracic region. MRI and MRS acquisition of the hepatic and&#xD;
      cervico-thoracic region will be repeated again at the end of the day.&#xD;
&#xD;
      The radioactive PET tracers used in this study are the [11C]-acetate, [11C]-palmitate and&#xD;
      [18F]-FDG followed by dynamic and whole-body scans.&#xD;
&#xD;
      Stable isotopes such as [U-13C]-palmitate (0.08 umol/kg/min), 5D-glycérol (0.1 µmol/kg/min,)&#xD;
      and tritiated glucose (of 1.5 uCi/min) will be perfused from the start of the day until time&#xD;
      180 min.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups in parallel (with and without Type 2 diabetes). In each group, the protocol will be carried out as a within-subject, randomized, cross-over study in which each subject will serve as his/her own control.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BAT volume</measure>
    <time_frame>180 minutes after the start of the cold exposure</time_frame>
    <description>Assessed using i.v. injection of 18FDG with whole-body PET/CT acquisition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brown Adipose Tissue (BAT) Glucose uptake</measure>
    <time_frame>150 minutes after the start of the cold exposure</time_frame>
    <description>Assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of BAT (oxidative metabolism)</measure>
    <time_frame>90 minutes after beginning cold exposure</time_frame>
    <description>Measured with 11C-acetate using dynamic PET/CT acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Acid uptake and metabolism</measure>
    <time_frame>at baseline and at time 120 minutes after beginning cold exposure</time_frame>
    <description>Measured with 11C-palmitate using dynamic PET/CT acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT triglyceride content</measure>
    <time_frame>at baseline and at time 180 (for CT) and 240 (for MR) after cold exposure.</time_frame>
    <description>Estimated by CT and MR using 1H-MRS and Dixon sequences on a 3T clinical MRI system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body lipolysis</measure>
    <time_frame>-150 and 0 minutes before and 60, 120 and 180 minutes after cold exposure.</time_frame>
    <description>Systemic appearance rate of glycerol and fatty acid determined by perfusion of [1,1,2,3,3-2H]-glycerol, [U-13C]-palmitate tracers and concentration of total NEFA, triglycerides, palmitate, oleate, linoleate, glycerol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Glucose production</measure>
    <time_frame>-150 and 0 minutes before and 60, 120 and 180 minutes after cold exposure.</time_frame>
    <description>Systemic appearance rate of glucose determined by perfusion of [3-3H]-glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substrate utilisation</measure>
    <time_frame>-150 and 0 minutes before and 60, 120 and 180 minutes after cold exposure.</time_frame>
    <description>VO2 and VCO2 will be measured by indirect calorimetry to calculate carbohydrate and fatty acid oxidation rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin level and secretion</measure>
    <time_frame>-150 and 0 minutes before and 60, 120 and 180 minutes after cold exposure.</time_frame>
    <description>measured with ELISA and Milliplex.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Subject with Type 2 Diabetes- cold exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-hour cold exposure: Protocol B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subject with type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-hour cold exposure with oral nicotinic acid: Protocol A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subject without Type 2 Diabetes- cold exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-hour cold exposure: Protocol B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subject without type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-hour cold exposure with oral nicotinic acid: Protocol A</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold exposure</intervention_name>
    <description>The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.</description>
    <arm_group_label>Subject with Type 2 Diabetes- cold exposure</arm_group_label>
    <arm_group_label>Subject with type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
    <arm_group_label>Subject without Type 2 Diabetes- cold exposure</arm_group_label>
    <arm_group_label>Subject without type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Nicotinic acid</intervention_name>
    <description>A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.</description>
    <arm_group_label>Subject with type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
    <arm_group_label>Subject without type 2 Diabetes- cold exposure and nicotinic acid</arm_group_label>
    <other_name>Niacin 500 (Jamp Pharma) NPN 00557412</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  10 men and 10 women with T2D.&#xD;
&#xD;
          -  10 non-diabetic men and 10 non-diabetic women (matched for sex, BMI and age to the T2D&#xD;
             participants).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in weight of more than 2 kg over the past 3 months or recent changes in&#xD;
             lifestyle;&#xD;
&#xD;
          -  Treatment with a fibrate, thiazolidinedione, insulin, beta-blocker, GLP-1 agonist, or&#xD;
             other drug known to affect lipid or carbohydrate metabolism, except statins,&#xD;
             metformin, sulfonylurea, DPP-IV inhibitor and other antihypertensive agents that can&#xD;
             be temporarily stopped safely prior to the studies, as per our approved protocols;&#xD;
&#xD;
          -  Presence of overt cardiovascular, liver, renal or other medical conditions;&#xD;
&#xD;
          -  Smoking or consumption of more than 2 alcoholic beverages per day;&#xD;
&#xD;
          -  Any other contraindication to temporarily suspending current medications for lipids or&#xD;
             hypertension;&#xD;
&#xD;
          -  Any contraindication to MRI scanning.&#xD;
&#xD;
          -  Having participated to a research study with exposure to radiation in the last two&#xD;
             years before the start of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Frisch</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12394</phone_ext>
    <email>frederique.frisch@Usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Frisch</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12394</phone_ext>
      <email>frederique.frisch@Usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>André Carpentier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Blondin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Turcotte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Lepage</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

